These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33216758)

  • 41. Combating the great mimicker: latest progress in the development of
    Khakhum N; Chapartegui-González I; Torres AG
    Expert Rev Vaccines; 2020 Jul; 19(7):653-660. PubMed ID: 32669008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei.
    Holden MT; Titball RW; Peacock SJ; Cerdeño-Tárraga AM; Atkins T; Crossman LC; Pitt T; Churcher C; Mungall K; Bentley SD; Sebaihia M; Thomson NR; Bason N; Beacham IR; Brooks K; Brown KA; Brown NF; Challis GL; Cherevach I; Chillingworth T; Cronin A; Crossett B; Davis P; DeShazer D; Feltwell T; Fraser A; Hance Z; Hauser H; Holroyd S; Jagels K; Keith KE; Maddison M; Moule S; Price C; Quail MA; Rabbinowitsch E; Rutherford K; Sanders M; Simmonds M; Songsivilai S; Stevens K; Tumapa S; Vesaratchavest M; Whitehead S; Yeats C; Barrell BG; Oyston PC; Parkhill J
    Proc Natl Acad Sci U S A; 2004 Sep; 101(39):14240-5. PubMed ID: 15377794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of Burkholderia pseudomallei Strains Using a Murine Intraperitoneal Infection Model and In Vitro Macrophage Assays.
    Welkos SL; Klimko CP; Kern SJ; Bearss JJ; Bozue JA; Bernhards RC; Trevino SR; Waag DM; Amemiya K; Worsham PL; Cote CK
    PLoS One; 2015; 10(4):e0124667. PubMed ID: 25909629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of Burkholderia mallei and pseudomallei vaccines.
    Silva EB; Dow SW
    Front Cell Infect Microbiol; 2013; 3():10. PubMed ID: 23508691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen.
    Stevens MP; Wood MW; Taylor LA; Monaghan P; Hawes P; Jones PW; Wallis TS; Galyov EE
    Mol Microbiol; 2002 Nov; 46(3):649-59. PubMed ID: 12410823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional characterizations of effector protein BipC, a type III secretion system protein, in Burkholderia pseudomallei pathogenesis.
    Kang WT; Vellasamy KM; Chua EG; Vadivelu J
    J Infect Dis; 2015 Mar; 211(5):827-34. PubMed ID: 25165162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei.
    Muruato LA; Tapia D; Hatcher CL; Kalita M; Brett PJ; Gregory AE; Samuel JE; Titball RW; Torres AG
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28903988
    [No Abstract]   [Full Text] [Related]  

  • 48. Cloning and analysis of genomic differences unique to Burkholderia pseudomallei by comparison with B. thailandensis.
    Brown NF; Beacham IR
    J Med Microbiol; 2000 Nov; 49(11):993-1001. PubMed ID: 11073153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Production and purification of Burkholderia pseudomallei BipD protein.
    Visutthi M; Jitsurong S; Chotigeat W
    Southeast Asian J Trop Med Public Health; 2008 Jan; 39(1):109-14. PubMed ID: 18567449
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis.
    Ngugi SA; Ventura VV; Qazi O; Harding SV; Kitto GB; Estes DM; Dell A; Titball RW; Atkins TP; Brown KA; Hitchen PG; Prior JL
    Vaccine; 2010 Nov; 28(47):7551-5. PubMed ID: 20837078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Burkholderia pseudomallei known siderophores and hemin uptake are dispensable for lethal murine melioidosis.
    Kvitko BH; Goodyear A; Propst KL; Dow SW; Schweizer HP
    PLoS Negl Trop Dis; 2012; 6(6):e1715. PubMed ID: 22745846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Burkholderia Hep_Hag autotransporter (BuHA) proteins elicit a strong antibody response during experimental glanders but not human melioidosis.
    Tiyawisutsri R; Holden MT; Tumapa S; Rengpipat S; Clarke SR; Foster SJ; Nierman WC; Day NP; Peacock SJ
    BMC Microbiol; 2007 Mar; 7():19. PubMed ID: 17362501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.
    Silva EB; Goodyear A; Sutherland MD; Podnecky NL; Gonzalez-Juarrero M; Schweizer HP; Dow SW
    Infect Immun; 2013 Dec; 81(12):4626-34. PubMed ID: 24101688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of novel animal infection models for the study of acute and chronic Burkholderia pseudomallei pulmonary infections.
    van Schaik E; Tom M; DeVinney R; Woods DE
    Microbes Infect; 2008 Oct; 10(12-13):1291-9. PubMed ID: 18707015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel multi-component vaccine approaches for Burkholderia pseudomallei.
    Morici L; Torres AG; Titball RW
    Clin Exp Immunol; 2019 May; 196(2):178-188. PubMed ID: 30963550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A DUF4148 family protein produced inside RAW264.7 cells is a critical Burkholderia pseudomallei virulence factor.
    Welkos S; Blanco I; Okaro U; Chua J; DeShazer D
    Virulence; 2020 Dec; 11(1):1041-1058. PubMed ID: 32835600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular characterization of putative virulence determinants in Burkholderia pseudomallei.
    Puah SM; Puthucheary SD; Wang JT; Pan YJ; Chua KH
    ScientificWorldJournal; 2014; 2014():590803. PubMed ID: 25215325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of differentially expressed proteins from Burkholderia pseudomallei isolated during primary and relapsing melioidosis.
    Velapatiño B; Limmathurotsakul D; Peacock SJ; Speert DP
    Microbes Infect; 2012 Apr; 14(4):335-40. PubMed ID: 22172334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibodies against
    Zimmerman SM; Dyke JS; Jelesijevic TP; Michel F; Lafontaine ER; Hogan RJ
    Infect Immun; 2017 Aug; 85(8):. PubMed ID: 28507073
    [No Abstract]   [Full Text] [Related]  

  • 60. In vivo expression technology identifies a type VI secretion system locus in Burkholderia pseudomallei that is induced upon invasion of macrophages.
    Shalom G; Shaw JG; Thomas MS
    Microbiology (Reading); 2007 Aug; 153(Pt 8):2689-2699. PubMed ID: 17660433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.